Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

ByQuantisnow·Wall Street's wire, on your screen.

Stocks in this Quantisnow insightHealth Care

ROIVNASDAQRoivant Sciences Ltd.
Alert me

Quantisnow market dataNASDAQ

ROIV

Roivant Sciences Ltd.

Market cap
30-day
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations

Get push alerts for ROIV

Follow ROIV and get a push notification the moment its next story breaks.

Full ROIV profile on Quantisnow

Delivered by Quantisnow

Get the next ROIV story the moment it breaks

Quantisnow reads SEC filings, FDA decisions, analyst ratings, insider trades and press releases straight off the wire and alerts you on the tickers you follow, so you read it before the market prices it in.

Push to your phoneQuantisnow app for iOS and Android
Email alertHeadline, tickers and the source link
Live feedStreams in as the wire publishes

Quantisnow Free vs Plus
Feature	Free	Plus
Delivery	On a delay	Real time, ~350ms
Followed tickers	Up to 5	Up to 250
Push + email alerts	Daily limit	Every story
Price	$0	$69/mo

Continue with Google Sign up with email Free to start. Plus is $69/mo